Importantly, PPA1-DOX exhibits a significantly improved antitumor activity in vivo, most likely by alleviating chemotherapeutic resistance of DOX and enhancing immune response in colon cancer. This evidence concerns the gene PPA1 and malignant colon neoplasm.